[Federal Register Volume 65, Number 115 (Wednesday, June 14, 2000)]
[Notices]
[Page 37394]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-14950]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 00146]


Cooperative Agreement With the Kenya Medical Research Institute; 
Notice of Availability of Funds

A. Purpose

    The Centers for Disease Control and Prevention (CDC) announces the 
availability of funds for fiscal year (FY) 2000 for a cooperative 
agreement program with the Kenya Medical Research Institute (KEMRI) to 
conduct complex research studies and related activities to control and 
prevent malaria, HIV/AIDS, and other diseases of public health 
importance in Kenya. CDC is committed to achieving the health promotion 
and disease prevention objectives of ``Healthy People 2010'', a 
national activity to reduce morbidity and mortality and improve the 
quality of life. This announcement is related to the focus areas of HIV 
and Immunization and Infectious Diseases. For the conference copy of 
``Healthy People 2010'', visit the internet site http://www.health.gov/healthypeople.
    The objectives of this proposal are:
    1. To assist KEMRI in the conduct of field and laboratory research 
on important human infectious diseases prevalent in Kenya with an 
emphasis on malaria and HIV.
    2. To improve the training of students and public health 
professionals in basic and applied public health research and the 
training of students and other professionals in the areas that provide 
support to research efforts such as data and financial management.
    3. To strengthen KEMRI institutional capacity to conduct research 
and training in public health.
    4. To incorporate the results of research into operational disease 
prevention and control programs in the Republic of Kenya and insure 
sharing of expertise and research findings with other nations.
    5. To determine national priority areas and develop human resources 
focused on public health.

B. Eligible Applicants

    Assistance will be provided only to KEMRI. No other applications 
are solicited. KEMRI is the most appropriate and qualified agency to 
conduct the activities specified under this cooperative agreement 
because:
    1. KEMRI is the only research organization in Kenya that possesses 
the requisite scientific and technical expertise, the infrastructure 
capacity and who has conducted longitudinal malaria and related HIV 
research in areas of high morbidity (20 years for malaria and 10 years 
for HIV/AIDS). These combined attributes make them the only 
organization in Kenya capable of effectively conducting the research 
proposed for this cooperative agreement.
    2. A major operational unit of KEMRI is located in western Kenya in 
an area of extremely high level malaria and HIV transmission, and thus 
is ideally located to evaluate approaches to preventing and controlling 
these public health problems.
    3. KEMRI was established through the Science and Technology Act of 
the Republic of Kenya and has a Board of Management appointed by the 
Minister of Health which is responsible for overseeing all research and 
which has a well-developed secretariat to provide administrative and 
technical support to research services.
    4. KEMRI has been collaborating with health agencies on priority 
infectious disease research for over 20 years on the grounds of the 
KEMRI facility both in Nairobi and Kisumu. The KEMRI Facility has 
experienced staff, equipment, and facilities to support the 
collaboration.

C. Availability of Funds

    Approximately $657,000 is available in FY 2000 to fund one award. 
It is expected that $574,000 will be available for malaria and 
infectious diseases and $83,000 will be for HIV/AIDS. It is expected 
that the award will begin on August 1, 2000, and will be made for a 5-
month budget period within a project period of up to five years. The 
funding estimate may change.
    Continuation awards within an approved project period will be made 
on the basis of satisfactory progress as evidenced by required reports 
and the availability of funds.

Use of Funds

    Indirect costs will not be provided on HHS Grants to international 
or foreign organizations where the grant is performed entirely outside 
the territorial limits of the United States.

D. Where to Obtain Additional Information

    If you have any questions after reviewing the content of all 
documents, business management technical assistance may be obtained 
from: Juanita D. Crowder, Grants Management Specialist, Grants 
Management Branch, Procurement and Grants Office, Centers for Disease 
Control and Prevention, Room 3000, 2920 Brandywine Road, Atlanta, GA 
30341-4146, Telephone: (770)488-2734, Email address: <a href="/cdn-cgi/l/email-protection#0f656b6b3d4f6c6b6c21686079"><span class="__cf_email__" data-cfemail="8ce6e8e8beccefe8efa2ebe3fa">[email protected]</span></a>.
    For program technical assistance, contact: Sue Binder, M.D., 
Division of Parasitic Diseases, National Center for Infectious 
Diseases, Centers for Disease Control and Prevention 1600 Clifton Road, 
Mailstop F-22, Atlanta, GA 30333, Telephone: (770)488-7793, Email 
address: <a href="/cdn-cgi/l/email-protection#b2c1d0dbdcd6d7c0f2d1d6d19cd5ddc4"><span class="__cf_email__" data-cfemail="89faebe0e7edecfbc9eaedeaa7eee6ff">[email protected]</span></a>.

    Dated: June 8, 2000.
Henry S. Cassell, III,
Acting Director, Procurement and Grants Office, Centers for Disease 
Control and Prevention (CDC).
[FR Doc. 00-14950 Filed 6-13-00; 8:45 am]
BILLING CODE 4162-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>